Article Text

Download PDFPDF
Prognostic Role of Hormone Receptors in Ovarian Cancer: A Systematic Review and Meta-Analysis
  1. Dong Zhao, MD*,
  2. Fengmei Zhang, BSc,
  3. Wei Zhang, BSc,
  4. Jing He, BSc,
  5. Yulan Zhao, MD, PhD and
  6. Jing Sun, MD*
  1. *Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine; and
  2. Institutes for Advanced Interdisciplinary Research and
  3. School of Life Science, East China Normal University, Shanghai, PR China.
  1. Address correspondence and reprint requests to Jing Sun, MD, Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 200040, PR China. E-mail: sunjing61867{at}; Yulan Zhao, MD, PhD, School of Life Science, East China Normal University, N Zhongshan Rd 3663, Shanghai City, PR China, 200062. E-mail: ylzhao{at}


Objective The aim of this study was to summarize the global predicting role of hormone receptors for survival in ovarian cancer.

Methods Eligible studies were identified and assessed for quality through multiple search strategies. Data were collected from studies comparing overall or progression-free/disease-free/relapse-free survival in patients with elevated levels of estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) with those in patients with lower levels. Studies were pooled, and combined hazards ratios (HRs) of ER, PR, and HER2 for survival were calculated, respectively.

Results A total of 35 studies were included for meta-analysis (23 for ER, 19 for PR, and 8 for HER2). For overall survival, the pooled HR of PR reached 0.88 [95% confidence interval (CI), 0.82-0.95], which means that elevated PR level could significantly indicate better survival. In contrast, elevated levels of HER2 could predict worse outcome with an HR of 1.41 (95% CI, 1.05–1.89). Increased level of ER was not significantly prognostic (HR, 0.94; 95% CI, 0.87–1.01). For progression-free survival/disease-free survival/recurrence-free survival, elevated PR level also had predictive value for better outcome with a pooled HR of PR of 0.80 (95% CI, 0.67–0.95). Oppositely, elevated HER2 level could predict poorer outcome with an HR of 1.55 (95% CI, 1.11–2.16). Estrogen receptor failed to predict outcome with an HR of 0.90 (95% CI, 0.78–1.03).

Conclusions In patients with ovarian cancer, elevated level of PR predicted favorable survival, and elevated level of HER2 was associated with worse survival.

  • Ovarian cancer
  • Estrogen receptor
  • Progesterone receptor
  • Human epidermal growth factor receptor 2
  • Prognosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Dong Zhao and Fengmei Zhang contributed equally to this work.

  • The analysis was supported by the National Natural Science Foundation of China (NSFC 30800401) and Shanghai Rising star program (08QA1407000).

  • The authors declare no conflicts of interest.

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (